Cullgen Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
115
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$300M
Cullgen General Information
Description
Cullgen Inc is clinical-stage biopharmaceutical company. The company is engaged in the development of medicines for the treatment of diseases lacking effective therapeutic approaches. The company utilizes its technology platform, uSMIT, featuring novel E3 ligands, to build the next generation of targeted protein degraders and to discover and advance therapeutics for the treatment of cancer and other diseases. The products in the company's pipeline include Degrader TRK, Degrader GSPT1, DAC, and others.
Contact Information
Website
www.cullgen.com(Operating Subsidiary)
Corporate Office
- 12730 High Bluff Drive
- Suite 250
- San Diego, CA 92130
- United States
Corporate Office
- 12730 High Bluff Drive
- Suite 250
- San Diego, CA 92130
- United States
Cullgen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 04-May-2026 | $300M | Completed | Clinical Trials - Phase 2 | ||
| 6. Reverse Merger | 13-Nov-2024 | Cancelled | Clinical Trials - Phase 2 | |||
| 5. Secondary Transaction - Private | 20-Nov-2023 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series C) | 13-Apr-2023 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series B) | 25-Feb-2021 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 10-Apr-2019 | $16M | $31M | Completed | Startup | |
| 1. Seed Round | 01-Mar-2018 | $15M | $15M | Completed | Startup |
Cullgen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | ||||||||
| Seed 2 | 5,000,000 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 4.69% |
| Seed 1 | 10,000,000 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 9.38% |
Cullgen Comparisons
Industry
Financing
Details
Cullgen Competitors (33)
One of Cullgen’s 33 competitors is Nurix Therapeutics, a Formerly VC-backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nurix Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Kymera Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Exo Therapeutics | Venture Capital-Backed | Cambridge, MA |
Cullgen Patents
Cullgen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026041008-A1 | Maleic acid derivatives and uses thereof | Pending | 20-Aug-2024 | ||
| WO-2025252190-A1 | Targeted degraders of werner syndrome recq helicase | Pending | 07-Jun-2024 | ||
| EP-4808941-A1 | Compounds and methods of treating cancers | Pending | 16-Nov-2023 | ||
| WO-2025103502-A1 | Compounds and methods of treating cancers | Inactive | 16-Nov-2023 | ||
| US-20260297081-A1 | Compounds and methods of treating cancers | Pending | 07-Mar-2023 | C07D417/12 |
Cullgen Signals
Cullgen Former Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3E Bioventures (China) | Venture Capital | Minority | ||
| CVI Investments | PE/Buyout | Minority | ||
| GNI Group | Corporation | Minority | ||
| HSG (Hong Kong) | Venture Capital | Minority | ||
| Heights Capital | Growth/Expansion | Minority |
Cullgen FAQs
-
When was Cullgen founded?
Cullgen was founded in 2018.
-
Where is Cullgen headquartered?
Cullgen is headquartered in San Diego, CA.
-
What is the size of Cullgen?
Cullgen has 115 total employees.
-
What industry is Cullgen in?
Cullgen’s primary industry is Drug Discovery.
-
Is Cullgen a private or public company?
Cullgen is a Private company.
-
What is the current valuation of Cullgen?
The current valuation of Cullgen is .
-
What is Cullgen’s current revenue?
The current revenue for Cullgen is .
-
How much funding has Cullgen raised over time?
Cullgen has raised $116M.
-
Who are Cullgen’s investors?
3E Bioventures (China), CVI Investments, GNI Group, HSG (Hong Kong), and Heights Capital are 5 of 17 investors who have invested in Cullgen.
-
Who are Cullgen’s competitors?
Nurix Therapeutics, Arvinas, Sorrento Therapeutics, Kymera Therapeutics, and Exo Therapeutics are some of the 33 competitors of Cullgen.
-
When was Cullgen acquired?
Cullgen was acquired on 04-May-2026.
-
Who acquired Cullgen?
Cullgen was acquired by Gyre Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process